Gestational diabetes & diabetes in pregnancy
Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies
Authors' conclusion
Sclerostin and LRP5 were detected in human placentas. The overexpression of placental sclerostin and LRP5 values in GDM compared with non-GDM pregnancies, as well as the positive association of placental sclerostin values with pregestational maternal body mass index and maternal fasting glucose concentrations may indicate the development of an adaptive mechanism in face of maternal hyperglycemia.
Study context
- Population
- Caucasian mothers with and without gestational diabetes mellitus (GDM) and their neonates admitted to a gynecology and obstetrics department of a university hospital
- Participants
- 26 vs 34
- Exposure
- GDM vs non-GDM pregnancies
- GDMn = 26
- Non-GDMn = 34reference
- Outcome
- Placental LRP5 (IHC and Western blotting) and sclerostin (IHC) expression
Methodological detailssingle university hospital
- Single university hospital
Main finding
As reported in the abstract
GDM
65.08
± 17.09 · histo-score (sclerostin)
Non-GDM
11.45
± 2.33 · histo-score (sclerostin)
GDM vs Non-GDM: P < 0.001 · GDM vs Non-GDM: P < 0.001
Observational data: associations, not effects.
Further findings
Correlations of placental sclerostin immunohistochemistry (IHC) intensity
- With LRP5 by IHC
- r = 0.529; P < .001
- With LRP5 by Western blotting
- r = 0.398; P = .008
- With pregestational maternal BMI
- r = 0.299; P = .043
- With maternal fasting glucose
- r = 0.475; P = .009
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →